Quantcast
Swiss reserved up to 8,640 doses of Merck’s COVID-19 drug – Metro US

Swiss reserved up to 8,640 doses of Merck’s COVID-19 drug

FILE PHOTO: A handout photo of an experimental COVID-19 treatment
FILE PHOTO: A handout photo of an experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP

ZURICH (Reuters) – The Swiss government said on Tuesday it had reserved up to 8,640 doses of Merck’s COVID-19 drug Molnupiravir.

The antiviral Molnupiravir should be available at the latest in January 2022, the government said in a statement, not communicating how much it has agreed to pay for the drug.

(Reporting by Silke Koltrowitz, editing by Kirsti Knolle)

More from our Sister Sites